Thursday, April 11, 2013 3:51:47 PM
Recent ELOX News
- Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/29/2024 08:11:23 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 03/21/2024 06:20:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2024 08:30:38 PM
- Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases • GlobeNewswire Inc. • 03/13/2024 03:42:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 09:32:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/25/2024 02:44:31 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/24/2024 10:11:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:11:02 PM
- Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:26:20 PM
- Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria • GlobeNewswire Inc. • 10/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:43 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/20/2023 05:26:02 PM
- Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/19/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:05:57 PM
- Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 09:15:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 02:14:41 PM
- Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013 • GlobeNewswire Inc. • 09/07/2023 01:00:52 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM